The
term “ESBL” is used to mean acquired class A β-lactamases that hydrolyse and
(usually) confer resistance to oxyimino- ‘2nd and 3rd generation’ cephalosporins,
e.g. cefuroxime, cefotaxime, ceftazidime and ceftriaxone, but not cephamycins
or carbapenems eg cefoxitin.
ESBLs
are not the only β-lactamases to confer resistance to cephalosporins while
sparing carbapenems, but are the most important. Moreover, as plasmid-mediated
enzymes, they have great potential for spread. They occur mostly in
Enterobacteriaceae (e.g. E. coli, Klebsiella species and Enterobacter species).
The
U.K. government has posted a consultation document. The document asks for feedback
in relation to the SMI B 59: detection of enterobacteriaceae producing extended
spectrum β lactamases.
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources